About seres therapeutics inc. - MCRB
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
MCRB At a Glance
Seres Therapeutics, Inc.
101 Cambridge Park Drive
Cambridge, Massachusetts 02140
| Phone | 1-617-945-9626 | Revenue | 789.00K | |
| Industry | Biotechnology | Net Income | 5.70M | |
| Sector | Health Technology | Employees | 66 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MCRB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.17 |
| Price to Sales Ratio | 167.277 |
| Price to Book Ratio | 3.216 |
| Price to Cash Flow Ratio | 118.16 |
| Enterprise Value to EBITDA | -1.883 |
| Enterprise Value to Sales | 214.426 |
| Total Debt to Enterprise Value | 0.49 |
MCRB Efficiency
| Revenue/Employee | 11,954.545 |
| Income Per Employee | 86,303.03 |
| Receivables Turnover | 1.526 |
| Total Asset Turnover | 0.006 |
MCRB Liquidity
| Current Ratio | 2.555 |
| Quick Ratio | 2.555 |
| Cash Ratio | 2.369 |
MCRB Profitability
| Gross Margin | -423.828 |
| Operating Margin | -11,910.139 |
| Pretax Margin | 721.926 |
| Net Margin | 721.926 |
| Return on Assets | 4.098 |
| Return on Equity | 19.641 |
| Return on Total Capital | 4.479 |
| Return on Invested Capital | 5.335 |
MCRB Capital Structure
| Total Debt to Total Equity | 187.629 |
| Total Debt to Total Capital | 65.233 |
| Total Debt to Total Assets | 60.036 |
| Long-Term Debt to Equity | 164.132 |
| Long-Term Debt to Total Capital | 57.064 |